Kumar Neil 4

What Happened

Neil Kumar, CEO of BridgeBio Pharma (BBIO), had 64,698 restricted stock units (RSUs) vest on February 16, 2026. The RSUs converted into 64,698 shares of common stock; 30,970 of those shares were withheld to satisfy tax withholding obligations at $75.25 per share, equal to $2,330,493. The net result was issuance of approximately 33,728 shares to Kumar. This activity is vesting/award-related (not an open-market buy or voluntary sale).

Key Details

• Transaction date: 2026-02-16; Form 4 filed: 2026-02-18 (appears timely under Section 16 rules).
• Conversion (exercise of derivative/RSU) entries: 33,544 + 19,600 + 11,554 = 64,698 shares vested/converted.
• Tax withholding: 30,970 shares withheld (Code F) at $75.25/share = $2,330,493.
• Net shares issued to insider: ~33,728 shares (64,698 vested − 30,970 withheld).
• Shares owned after transaction: not specified in the report.
• Footnotes: RSUs represent contingent rights to common stock (F1); F2 confirms the withheld shares were to satisfy tax obligations; F4–F6 describe the RSU vesting schedule; F3 contains a standard beneficial ownership disclaimer.
• Transaction codes: M = exercise/conversion of a derivative (RSU conversion); F = shares withheld for tax withholding.

Context

• This was a standard RSU vesting and tax-withholding settlement (effectively a cashless settlement), not an open-market sale or purchase. Withholding of shares to cover taxes is common and does not necessarily indicate a change in insider sentiment.
• No 10b5-1 plan or late filing is indicated in the filing.